Is LivaNova Plc overvalued or undervalued?

As of 7 May 2025, LivaNova Plc's valuation grade has moved from very attractive to risky, indicating a significant deterioration in its investment appeal. The company is currently assessed as overvalued, primarily due to its negative financial metrics. Key ratios include a Price to Book Value of 2.45, an EV to EBIT of -13.31, and an EV to EBITDA of -18.71, all suggesting underlying financial challenges. When compared to peers, LivaNova's P/E ratio is notably negative at -9.23, while Glaukos Corp. also presents a risky profile with a P/E of -47.09. In contrast, CONMED Corp. is rated fair with a P/E of 19.36, highlighting the disparity in valuation within the sector. Additionally, LivaNova's recent stock performance has been underwhelming, with a one-year return of -18.86%, significantly lagging behind the S&P 500's 10.26% return, further reinforcing the notion of overvaluation.